Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
REDWOOD CITY, Calif., April 24, 2024 Coherus BioSciences, Inc. today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the.
D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study Evaluating streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.